Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
B05ZA	CONCENTRATE SOLUTION FOR HEMODIALYSIS LS	G	Potassium chloride - K+:1.5 mmol/l, Magnesium chloride - Mg++:0.75 mmol/l, Calcium chloride - Ca++:1.75 mmol/l, Sodium acetate - Cl-:111.5 mmol/l, Sodium chloride - Na+:140 mmol/l		Injectable solution	L.L
L01BC06	CAPECITABINE SPC	G	Capecitabine - 150mg	150mg	Tablet, film coated	4,094,240 L.L
B05ZA	CONCENTRATE SOLUTION FOR HEMODIALYSIS LS2	G	Potassium chloride - K+:1.5 mmol/l, Magnesium chloride - Mg++:0.75 mmol/l, Calcium chloride - Ca++:1.5 mmol/l, Sodium acetate - Cl-:111 mmol/l, Sodium chloride - Na+:140 mmol/l		Injectable solution	L.L
B05ZA	CONCENTRATE SOLUTION FOR HEMODIALYSIS LS3	G	Potassium chloride - K+:2.00 mmol/l, Magnesium chloride - Mg++:0.75 mmol/l, Calcium chloride - Ca++:1.60 mmol/l, Sodium acetate - Cl-:112 mmol/l, Sodium chloride - Na+:140 mmol/l		Injectable solution	L.L
B05ZA	CONCENTRATE SOLUTION FOR HEMODIALYSIS R	G	Potassium chloride - K+:1.00 mmol/l, Magnesium chloride - Mg++:0.75 mmol/l, Calcium chloride - Ca++:1.40 mmol/l, Sodium acetate - Cl-:105.8 mmol/l, Sodium chloride - Na+:140.5 mmol/l		Injectable solution	L.L
C09DB07	CANDAM	G	Candesartan cilexetil - 8mg, Amlodipine - 5mg		Capsule, hard	1,376,095 L.L
B05ZA	CONCENTRATE SOLUTIONFOR HEMODIALYSIS TYPE A	G	Hemodialytics, concentrates -		Injectable solution	L.L
C09DB07	CORONOPINE	G	Candesartan cilexetil - 8mg, Amlodipine - 5mg		Capsule, hard	1,368,032 L.L
B05ZA	CONCENTRATE SOLUTION FOR HEMODIALYSIS TYPE B+	G	Hemodialytics, concentrates -		Injectable solution	L.L
C09DB07	CANDAM	G	Candesartan cilexetil - 16mg, Amlodipine - 5mg		Capsule, hard	1,376,095 L.L
B05ZA	CONCENTRATE SOLUTION FOR HEMODIALYSIS TYPE J	G	Hemodialytics, concentrates -		Injectable solution	L.L
C09DB07	CORONOPINE	G	Candesartan cilexetil - 16mg, Amlodipine - 5mg		Capsule, hard	1,638,144 L.L
C09DB07	CANDAM	G	Candesartan cilexetil - 16mg, Amlodipine - 10mg		Capsule, hard	1,376,095 L.L
C09DB07	CORONOPINE	G	Candesartan cilexetil - 16mg, Amlodipine - 10mg		Capsule, hard	1,540,044 L.L
C09DB07	CORONOPINE	G	Candesartan cilexetil - 8mg, Amlodipine - 10mg		Capsule, hard	1,368,032 L.L
A03FA08	CINITREX	G	Cinitapride - 1mg	1mg	Tablet	636,981 L.L
N06BX03	CEBROTONIN	G	Piracetam - 800mg	800mg	Tablet, film coated	577,852 L.L
S01CA01	CO-AVAZIR	G	Tobramycin - 0.3%, Dexamethasone - 0.1%		Drops suspension	193,513 L.L
J02AX04	CANDIGARD	G	Caspofungin (acetate) - 70mg	70mg	Injectable powder for concentrate for solution	22,127,179 L.L
N06BX06	CEROLINE	G	Citicoline - 100mg/ml	100mg/ml	Solution	894,615 L.L
J02AX04	CASPOFUNGINE STRAGEN	G	Caspofungin (acetate) - 70mg	70mg	Injectable concentrated powder for solution	22,928,852 L.L
L01CA02	CELLCRISTIN	G	Vincristine sulfate - 1mg/ml	1mg/ml	Injectable solution	1,443,287 L.L
J01DE01	CEFIPEX 500 BENTA	G	Cefepime (hydrochloride) - 500mg	500mg	Injectable solution	545,216 L.L
J01DE01	CEFEPIME LDP LABORATORIOS TORLAN	G	Cefepime - 1g	1g	Injectable powder for solution	5,933,065 L.L
J02AX04	CANDIGARD	G	Caspofungin (acetate) - 50mg	50mg	Injectable powder for concentrate for solution	22,127,179 L.L
J01DE01	CEFEPIME PANPHARMA	G	Cefepime - 1g	1g	Injectable powder for solution	5,933,065 L.L
J02AX04	CASPOFUNGINE STRAGEN	G	Caspofungin (acetate) - 50mg	50mg	Injectable concentrated powder for solution	18,712,833 L.L
J01DE01	CEFIPEX 1000 BENTA	G	Cefepime - 1,000mg	1,000mg	Injectable dry powder+diluent	703,918 L.L
B01AC04	CERUVIN	G	Clopidogrel (Bisulfate) - 75mg	75mg	Tablet	240,548 L.L
J01DE01	CEFIPEX 1000 BENTA	G	Cefepime (hydrochloride) - 1,000mg	1,000mg	Injectable solution	703,918 L.L

...